#United States #San Diego #Alzheimer's Disease #Linus Health #CTAD 2025

Linus Health's Innovations in Alzheimer's Detection at CTAD 2025

During the 18th annual Clinical Trials on Alzheimer's Disease (CTAD) conference, held from December 1-4, 2025, at the Hilton San Diego Bayfront, Linus Health, a Boston-based AI-driven brain health company, came into the spotlight with its groundbreaking AI-enabled solutions aimed at advancing early detection of cognitive impairment, particularly Alzheimer’s disease. The company's research emphasized how its digital cognitive assessment platform can play a vital role in identifying early signs of Alzheimer’s, thereby improving patient outcomes and streamlining the clinical trial process.

Linus Health plans to present five scientific posters during CTAD 2025, each underscoring its commitment to enhancing cognitive impairment detection and clinical trial innovation. Three of these presentations reveal significant findings related to the electronic Person-Specific Outcome Measure (ePSOM) tool. This innovative tool is designed to capture meaningful outcomes that resonate most with individuals living with Alzheimer’s. The remaining two posters focus on Linus Health’s Digital Clock and Recall (DCR) and Digital Assessment of Cognition (DAC) tools, showcasing their remarkable accuracy in identifying Alzheimer’s risk and treatment eligibility.

Key Findings from Linus Health's Research

1. Poster P313: This research highlights the ePSOM tool's applicability in Japanese memory clinics, providing interim data that supports its feasibility, high acceptability, and adaptability across cultures for multinational Alzheimer’s trials. Key authors of this study include Dr. Atsushi Iwata and Dr. Hisatomo Kowa.

2. Poster P315: Findings indicate that self-reported confidence in areas like memory significantly correlates with cognitive impairment status, demonstrating ePSOM's capability to detect early cognitive changes more effectively than traditional measures. This poster features contributions from Dr. Stina Saunders and Dr. Claudio Toro-Serey, among others.

3. Poster P340: This presentation details how the Digital Clock and Recall tool reliably identifies treatment-eligible patients by assessing cognitive impairment within a concise three-minute timeframe. Authors of this study include Dr. Ali Jannati and Dr. Karl Thompson.

4. Poster P343: The DAC assessment’s ability to predict blood biomarker status for Alzheimer's, including in cognitively unimpaired individuals, indicates its potential for scalable remote screenings in both trials and general brain health assessments. This significant research was led by Dr. Ali Jannati and Dr. Karl Thompson once more.

5. Poster P306: This study validates the ePSOM tool's effectiveness in capturing relevant personal priority outcomes, emphasizing how worse cognitive performance correlates with lower self-reported confidence. Key contributors include Dr. Stina Saunders and Dr. Craig Ritchie.

Emphasis on Digital Assessments

Dr. John Showalter, COO of Linus Health, stated, "Digital assessments that can both detect subtle cognitive changes and reflect what truly matters to patients are critical to advancing clinical research and care." The findings presented at CTAD highlight how these AI-enhanced tools not only facilitate early detection of Alzheimer's risk but also make the clinical trials more efficient and diverse.

In addition to the posters, Linus Health announced that a manuscript detailing the capabilities of its DCR assessment has been accepted for publication in 'Alzheimer's Research Therapy.' This study shows that the DCR can detect cognitive impairment and estimate amyloid positivity within three minutes, underscoring a new approach to identifying Alzheimer's disease-related changes.

Linus Health will also engage with various life science partners throughout CTAD to discuss its digital tools' potential benefits in recruitment, outcome measures, and generating real-world evidence in Alzheimer’s research. Attendees can visit Linus Health's virtual booth for more information on the company's solutions.

Dr. David Bates, CEO and co-founder, articulated, "CTAD brings together leading minds focused on Alzheimer's research and innovation," and underscored the critical nature of person-centered assessments enabled by technology, all aimed at better brain health outcomes globally.

Conclusion

As the conference approaches, Linus Health is positioned as a leader in leveraging artificial intelligence for brain health, offering practical tools to empower patients and clinicians alike. The focus on early detection and real-world application of their findings promises to hold great potential for the future of Alzheimer’s research and treatment.

For those interested in scheduling a meeting with Linus Health during CTAD, more information can be found on their official meetings page.

For further inquiries, visit Linus Health for more about their innovations in proactive brain health.